Elan shares plummet 50% amid fresh Tysabri scare
The Elan share price has collapsed by more than 50% on the Irish Stock Exchange this morning after two new cases of the brain disease PML were identified in patients using its drug Tysabri.
The drug is used to treat multiple sclerosis and the new incidences are the first reported cases of PML since Tysabri was re-introduced to the market two years ago.





